Anju Software acquires ClinPlus

THE CLINPLUS PLATFORM, pictured above displayed on a computer screen, is a software suite designed for conducting clinical trials in the life sciences industry. Anju Software Inc., a company backed by Providence Equity Partners, announced its acquisition of ClinPlus on July 31. / COURTESY CLINPLUS
THE CLINPLUS PLATFORM, pictured above displayed on a computer screen, is a software suite designed for conducting clinical trials in the life sciences industry. Anju Software Inc., a company backed by Providence Equity Partners, announced its acquisition of ClinPlus on July 31. / COURTESY CLINPLUS

PROVIDENCE – Anju Software Inc., a New York-based software company serving the life sciences sector and backed by Providence Equity Partners LLC, has acquired the ClinPlus product suite for conducting and managing clinical trials electronically.

ClinPlus was previously a division of DZS Software Solutions Inc., a clinical services and analytics firm based in New Jersey. The ClinPlus eClinical Platform combines electronic data capture, interactive web-response systems, clinical trial management systems, and electronic trial master-file software into a single platform.

DZS will retain DZS Clinical Services, the company’s contract research division, which conducts clinical studies for the biotech and pharmaceutical industries. DZS will continue to use the ClinPlus product suite in conducting its own trials but has sold ownership of the ClinPlus platform to Anju, according to a July 31 release.

Anju Software is a portfolio company of Providence Strategic Growth, the growth-equity affiliate of Providence Equity Partners, a global private-equity firm headquartered in Providence with $50 billion in assets under management.

- Advertisement -

“We are pleased with the execution of the growth strategy of Anju with ClinPlus being the third acquisition in a year,” Gopi Vaddi, managing director of the Providence Strategic Growth Fund, said in a statement. “After having established a dominant position in medical affairs with the acquisition of OBA and OpenIQ, ClinPlus will enable Anju to enter and grow in the clinical trial space.”

Anju CEO Kurien Jacob added that the acquisition of ClinPlus is consistent with Anju’s strategy of enhancing its product offering through acquisitions and internal development. With the ClinPlus suite, Anju can now provide full clinical-trial software support, Jacob said.

“Anju will accelerate the growth of ClinPlus as part of their overall consolidation and growth strategy, which is at a stage where the additional resources that Anju can provide are essential,” said DZS President Doron Steger of the acquisition.

Snell and Wilmer acted as legal advisers to Anju Software, and Madison Park Group acted as investment banking advisers to Anju on this transaction.

Kaylen Auer is a PBN contributing writer.

No posts to display